Previous 10 | Next 10 |
Aridis Pharmaceuticals Announces Third Quarter 2020 Results PR Newswire SAN JOSE, Calif., Nov. 20, 2020 SAN JOSE, Calif. , Nov. 20, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and deve...
The following slide deck was published by Aridis Pharmaceuticals, Inc. in conjunction with this event. For further details see: Aridis Pharmaceuticals (ARDS) Investor Presentation - Slideshow
/C O R R E C T I O N -- Aridis Pharmaceuticals, Inc./ PR Newswire SAN JOSE, Calif., Oct. 27, 2020 In the news release, Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel, issued 27-Oct-2020 by Aridis P...
Aridis Pharmaceuticals to Present at the ROTH Capital Partners 2020 MedTech Innovation Forum on a COVID-19 Panel PR Newswire SAN JOSE, Calif., Oct. 27, 2020 SAN JOSE, Calif. , Oct. 27, 2020 /PRNewswire/ -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopha...
Ultra-thinly traded nano cap Aridis Pharmaceuticals (ARDS) perks up 7% premarket on light volume in reaction to its announcement of preclinical data supporting the potential efficacy of an inhalable formulation of AR-711, a neutralizing monoclonal antibody, for treating COVID-19.In ...
Aridis Pharmaceuticals Reports Positive Preclinical Efficacy Data of a Highly Effective Inhaled Treatment Supporting a Proposed Self-Administered Therapy for COVID-19 Patients PR Newswire SAN JOSE, Calif., Oct. 19, 2020 SAN JOSE, Calif. , Oct. 19, 2020 /PRNew...
Aridis Pharmaceuticals (ARDS) enters agreement with institutional investors for the sale of 1,134,470 shares of common stock at $7.4925 per share, for a gross proceed of $8.5M.In a concurrent private placement, the investors agreed to purchase two series of warrants for an aggregate 567,234 s...
Aridis Pharmaceuticals Announces $8.5 Million Registered Direct Offering Company Enters Into Securities Purchase Agreement with Institutional Investors PR Newswire SAN JOSE, Calif., Oct. 14, 2020 SAN JOSE, Calif. , Oct. 14, 2020 /PRNewswire/ -- Aridis Pha...
Albireo reports positive data from Phase 3 trial Albireo Pharma, Inc. (ALBO) reported positive top-line data from PEDFIC 1 trial for odevixibat. The study met both its primary endpoints. The drug candidate is a highly potent, non-systemic ileal bile acid transport inhibitor. It is being ...
Aridis Pharmaceuticals (NASDAQ: ARDS ) has reached an agreement with the FDA to simplify its AR-501 Phase 2 trial design for the treatment of chronic lung infections associated with cystic fibrosis (CF). More news on: Aridis Pharmaceuticals, Inc., Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aridis Pharmaceuticals Inc. Company Name:
ARDS Stock Symbol:
NASDAQ Market:
Aridis Pharmaceuticals Inc. Website:
Biomerieux (BMXMF) is expected to report for Q1 2024 Conn's Inc. (CONN) is expected to report $-0.65 for Q1 2025 Cognetivity Neurosciences Ltd (CGNSF) is expected to report for quarter end 2024-04-30 Aridis Pharmaceuticals Inc. (ARDS) is expected to report for Q1 2024 China Jo-Jo ...
DS Smith Plc. (DITHF) is expected to report for Q4 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Harbour Energy Plc ADR (HBRIY) is expected to report for Q1 2024 Bayerische Motoren Werke AG (BAMXF) is expected to report for Q1 2024 ...
Commercial Metals Company (CMC) is expected to report $1 for Q3 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 GMS Inc. (GMS) is expected to report $2.04 for Q4 2024 China Jo-Jo Drugstores Inc. (CJJD) is expected to report for Q4 2024 Eiger BioPharmaceuticals Inc. (EIGR...